Organogenesis 10-Q: Revenue Down 70%, Cash Falls to $21.3M, Amnuvx BLA Timeline Slips
ORGO is trading near its 52-week low of $0.73 (7.9% above the low).
Summary
Organogenesis' Q3 10-Q confirms the 70% revenue collapse and shows cash down to $21.3 million with no debt and only an uncommitted ATM for liquidity, while the Amnuvx BLA timeline slips after 18 FDA inspection findings.
Key Events · Earnings and Guidance · ORGO
-
Q3 Revenue Falls 70%
Net product revenue was $45.5 million versus $150.5 million a year ago, with Advanced Wound Care down 73% to $38.2 million after the LCD withdrawal and CMS discarded-product comments disrupted the market.
-
Cash Down to $21.3M
Cash and cash equivalents fell to $21.3 million from $93.7 million at December 31, 2025 ($26.9 million including restricted cash), against a $179.1 million nine-month net loss and $29.1 million of operating cash burn; the company has no outstanding debt.
-
Liquidity Rests on Uncommitted ATM
Of the $75.0 million ATM program, $73.2 million remained available at September 30, 2026, but the company states it is not committed financing and sales have been slow; only 1,119,180 shares were sold for $1.4 million net.
-
Amnuvx BLA Timeline Slips
The FDA's Pre-License Inspection of the Norwood facility identified 18 items requiring remediation, now expected complete by September 30, 2027, and the PDUFA target action date is expected to be extended from April 24, 2027.
Analysis · ORGO · Life Sciences
The headline numbers were already out via the same-day 8-K, but the full 10-Q shows how thin the cushion is: cash and equivalents of $21.3 million against a $179.1 million nine-month net loss and $29.1 million of operating cash burn. Beyond that, the only committed liquidity is an at-the-market program with $73.2 million of unused capacity that management itself says is not committed financing and has sold slowly. On top of that, the FDA's pre-license inspection of the Norwood facility flagged 18 items requiring remediation, pushing the expected completion to September 30, 2027 and extending the Amnuvx PDUFA date beyond April 24, 2027 — the one near-term product catalyst now slips a year. A full valuation allowance against deferred tax assets confirms management no longer expects taxable profits in the foreseeable future.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORGO was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.1M. The 52-week trading range was $0.73 to $7.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.